Cybin
- Market cap
- 767.86M
- P/E (TTM)i
- -2.47
- P/Bi
- 3.31
- EPSi
- -4.25
- Div yieldi
- 0.00%
- 52W posi
- 59%
Anonymous reader poll. Unscientific, not investment advice.
About Cybin
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
- Founded
- 2016
- CEO
- Mr. Eric So
- Employees
- 50
- Headquarters
- Toronto, Ontario, Canada
- Fiscal year end
- 03-31
- Website
- helus.com
Company profile
- Exchange
- US
- Symbol
- HELP
- Market-cap rank
- #3447
- Market cap
- 767.86M
- Float cap
- 614.64M
- Shares out
- 73.06M
- Float shares
- 58.48M
Sectors & themes
Quote time 2026-10-08 08:57:22 · For reference only, not investment advice and not tailored to your situation.